RE:RE:RE:RE:RE:RE:RE:RE:Another hypotheticalStable disease would not prove anything on such a small sample of patients treated for such a small amount of time. If you want the SP up on news, you will need to see efficacy on tumor size in some patients. Again, if they would have tumor size reduction correlated with sortilin overexpression, that would be good, even if the tumor reduction is not qualified as a partial response (30% or more size reduction.) You need something that proves that the PDC is internalized and that it allows a tangible effect on the tumor. If they don't have it, the SP will not move up, and it may go down.
Wino115 wrote: My non-scientific view would be only a little, but that's more solid for proof of the concept -- sortilin is a valid target, the peptide attaches, it internalizes, somethings happening. Beyond that it may get harder and you'd need to use that data point with others.
For instance, if it was stable in all the colon cancer targets, well that's pretty remarkable because they showed docetaxol standard care doesn't really do anything in colon cancer. So if you just showed stability, that means it's getting in there where normal chemo does nothing.
I'm good with just seeing solid safety, decent chemo bomb dosage, anything the prove the target and peptide construction. That will help me eliminate the big negative tail around any Phase 1 drug trial. It won't eliminate it all since efficacy will be part 1b, but it will eliminate a bit of it and shift the possible outcome curve a tad more positive on top. The test will be 1b.